Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

The effect of N-acetylcysteine on the antitumor activity of ifosfamide.

Chen N, Hanly L, Rieder M, Yeger H, Koren G.

Can J Physiol Pharmacol. 2011 May;89(5):335-43. doi: 10.1139/y11-028.

PMID:
21609276
2.

The effect of N-acetylcysteine on ifosfamide-induced nephrotoxicity: in vitro studies in renal tubular cells.

Chen N, Aleksa K, Woodland C, Rieder M, Koren G.

Transl Res. 2007 Jul;150(1):51-7.

PMID:
17585863
3.

The Effects of N-acetylcysteine on ifosfamide efficacy in a mouse xenograft model.

Hanly L, Figueredo R, Rieder MJ, Koropatnick J, Koren G.

Anticancer Res. 2012 Sep;32(9):3791-8.

PMID:
22993321
4.

N-Acetylcysteine prevents ifosfamide-induced nephrotoxicity in rats.

Chen N, Aleksa K, Woodland C, Rieder M, Koren G.

Br J Pharmacol. 2008 Apr;153(7):1364-72. doi: 10.1038/bjp.2008.15.

5.

N-acetylcysteine as a novel prophylactic treatment for ifosfamide-induced nephrotoxicity in children: translational pharmacokinetics.

Hanly LN, Chen N, Aleksa K, Cutler M, Bajcetic M, Palassery R, Regueira O, Turner C, Baw B, Malkin B, Freeman D, Rieder MJ, Vasylyeva TL, Koren G.

J Clin Pharmacol. 2012 Jan;52(1):55-64. doi: 10.1177/0091270010391790.

PMID:
21263015
6.

Thermodynamic analysis of the reaction of phosphoramide mustard with protector thiols.

Seitz DE, Katterjohn CJ, Rinzel SM, Pearce HL.

Cancer Res. 1989 Jul 1;49(13):3525-8.

7.

Ifosfamide nephrotoxicity in children: a mechanistic base for pharmacological prevention.

Hanly L, Chen N, Rieder M, Koren G.

Expert Opin Drug Saf. 2009 Mar;8(2):155-68. doi: 10.1517/14740330902808169 . Review.

PMID:
19309244
8.

N-acetylcysteine rescue protocol for nephrotoxicity in children caused by ifosfamide.

Hanly L, Rieder MJ, Huang SH, Vasylyeva TL, Shah RK, Regueira O, Koren G.

J Popul Ther Clin Pharmacol. 2013;20(2):e132-45.

PMID:
23775286
9.

Ifosfamide metabolites CAA, 4-OH-Ifo and Ifo-mustard reduce apical phosphate transport by changing NaPi-IIa in OK cells.

Patzer L, Hernando N, Ziegler U, Beck-Schimmer B, Biber J, Murer H.

Kidney Int. 2006 Nov;70(10):1725-34.

10.

Prevention of ifosfamide nephrotoxicity by N-acetylcysteine: clinical pharmacokinetic considerations.

Chen N, Aleksa K, Woodland C, Rieder M, Koren G.

Can J Clin Pharmacol. 2007 Summer;14(2):e246-50. Review.

PMID:
17652768
11.

Glufosfamide as a new oxazaphosphorine anticancer agent.

Mazur L, Opydo-Chanek M, Stojak M.

Anticancer Drugs. 2011 Jul;22(6):488-93. doi: 10.1097/CAD.0b013e328345e1e0. Review.

PMID:
21427562
12.

Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy.

Foxall PJ, Singer JM, Hartley JM, Neild GH, Lapsley M, Nicholson JK, Souhami RL.

Clin Cancer Res. 1997 Sep;3(9):1507-18.

13.

Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children.

Loebstein R, Atanackovic G, Bishai R, Wolpin J, Khattak S, Hashemi G, Gobrial M, Baruchel S, Ito S, Koren G.

J Clin Pharmacol. 1999 May;39(5):454-61.

PMID:
10234592
14.

Comparison of N-acetylcysteine and mesna as uroprotectors with ifosfamide combination chemotherapy in refractory germ cell tumors.

Munshi NC, Loehrer PJ Sr, Williams SD, Langefeld C, Sledge G, Nichols CR, Roth BJ, Neuman A, Walsh WB, Einhorn LH.

Invest New Drugs. 1992 Aug;10(3):159-63.

PMID:
1428725
15.

Ifosfamide in the treatment of pediatric malignancies.

Voƻte PA, van den Berg H, Behrendt H, Michiels E, de Kraker J.

Semin Oncol. 1996 Jun;23(3 Suppl 7):8-11.

PMID:
8711502
16.

N-acetylcysteine and endothelial cell injury by sulfur mustard.

Atkins KB, Lodhi IJ, Hurley LL, Hinshaw DB.

J Appl Toxicol. 2000 Dec;20 Suppl 1:S125-8.

17.

Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group randomized study (E1588).

Ettinger DS, Finkelstein DM, Ritch PS, Lincoln ST, Blum RH; Eastern Cooperative Oncology Group..

Lung Cancer. 2002 Sep;37(3):311-8.

PMID:
12234701
18.

New ifosfamide analogs designed for lower associated neurotoxicity and nephrotoxicity with modified alkylating kinetics leading to enhanced in vitro anticancer activity.

Storme T, Deroussent A, Mercier L, Prost E, Re M, Munier F, Martens T, Bourget P, Vassal G, Royer J, Paci A.

J Pharmacol Exp Ther. 2009 Feb;328(2):598-609. doi: 10.1124/jpet.108.144170.

20.

Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.

Vanhoefer U, Schleucher N, Klaassen U, Seeber S, Harstrick A.

Semin Oncol. 2000 Feb;27(1 Suppl 1):8-13.

PMID:
10697038

Supplemental Content

Support Center